Our gene silencing platform technology can be licensed to develop therapies for multiple human diseases and conditions, including cancers, neurological diseases, infectious diseases, autoimmune diseases and other diseases related to gene disorders. Target-specific exclusive and non-exclusive licenses are available for a broad range of gene targets. Contact Us
Benitec Biopharma operates a virtual model, conducting in-house therapeutic programs by outsourcing strategic components of our R&D. We have selected a small number of disease conditions which demonstrate efficacy and safety of the technology in key fields (cancer, infectious disease, genetic disease and CNS), have viable delivery options, have high commercial potential and have realistic regulatory pathways.
Our plan is to progress our in-house therapeutic programs to proof of concept studies, Phase I and II trials before seeking to license the programs to pharmaceutical companies. Contact Us
We also seek immediate opportunities to leverage our ddRNAi platform technology for a wide range of therapeutics, via joint ventures with biotech and pharma companies.
Co-development inquiries are welcomed from groups with an interest in taking an early option on one or more of our in-house programs. Contact Us
We are also monetizing ddRNAi technology in the form of research tools which are available through technology licensing. Contact Us
